Total revenues from North America, excluding Bystolic, were $455.8 million for the three months ended Sept. 30, 2008 compared to $397.0 million for the same prior year period, representing an increase of $58.8 million. Of this increase, approximately $30.7 million is the result of the newly acquired businesses.
The remaining increase in revenues is primarily the result of continued strong sales of Mylan's Fentanyl Transdermal System ("fentanyl") and new product launches, partially offset by unfavorable pricing as a result of additional generic competition on certain products in the company's portfolio. Volumes for the quarter, excluding the impact of the acquisition, were consistent as compared to the prior year.
Fentanyl, Mylan's AB-rated generic alternative to Duragesic(R), continued to contribute significantly to the financial results. Despite the entrance into the market of additional generic competition in August 2007, sales of fentanyl have increased primarily due to Mylan's ability to continue to supply the market while certain competitors have recalled their versions of the fentanyl patch. The company expects additional competition in the future that may impact pricing and market share. In the current quarter, new products launched in the United States contributed revenues of $67.9 million.
Total revenues from EMEA and Asia Pacific, as well as revenues from the Specialty Segment, were all the result of the acquisition. For EMEA, revenues for the quarter ended Sept. 30, 2008, were $393.9 million, the majority of which are derived from the three largest markets; France, the United Kingdom and Germany. Total revenues from Asia Pacific were $137.6 million for the three months ended Sept. 30, 2008, and were derived from Mylan's acquired operations in Australia, Japan and New Zealand.
Matrix reported third-party revenues of $90.3 million for the three
|SOURCE Mylan Inc.|
Copyright©2008 PR Newswire.
All rights reserved